Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

859

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

April 30, 2010

Conditions
Alzheimer's Disease
Interventions
DRUG

Rivastigmine transdermal patch

"Rivastigmine transdermal patch was provided in the following sizes and doses:~2.5 cm\^2 (4.5 mg), 5 cm\^2 (9 mg), 7.5 cm\^2 (13.5 mg), and 10 cm\^2 (18 mg). The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day."

DRUG

Placebo

Placebo transdermal patch was provided in the following sizes: 2.5 cm\^2, 5 cm\^2, 7.5 cm\^2 and 10 cm\^2. The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.

Trial Locations (1)

Unknown

Novartis Investigative Site, Hokkaido Region

Sponsors
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

lead

Novartis Pharmaceuticals

INDUSTRY